“…Other barrels were filled with the AMPA/kainate receptor antagonist 1,2,3,4-tetrahydro-6-nitro-2,3-dioxo-benzo[f]quinoxaline-7-sulfonamide (NBQX) (5 mM, pH 9.0, vehicle 0.9% physiologic saline; Sigma, St. Louis, MO), the NMDA receptor antagonist (Ϯ)-3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid (CPP) (10 mM, pH 8.0, vehicle 0.9% physiologic saline), the GABA A receptor (GABA A R) antagonists bicuculline (10 mM, pH 3.0, vehicle 0.9% physiologic saline; Sigma) or gabazine (SR95531, 3 mM, pH 4.0, vehicle 0.9% physiologic saline; Tocris Bioscience, Ellisville, MO), and the glycine receptor (GlyR) antagonist strychnine (10 mM, pH 3.0, vehicle 0.9% physiologic saline; Fluka, Milwaukee, WI). The rationale for our choice of glutamate blockers was described previously (Sanchez et al, 2007).…”